Completed PHASE2 INTERVENTIONAL 4-arm NCT01275105

A Single-Center, Randomized, Double-Masked, Placebo and Active Controlled, Dose-Ranging Evaluation of the Duration of Action of Brimonidine Tartrate Ophthalmic Solution in the Control of Ocular Redness Induced by Conjunctival Allergen Challenge (CAC)

Sponsor: Eye Therapies, LLC

Interventions Brimonidine Tartrate 0.01% Brimonidine Tartrate 0.025% Oxymetazoline HCl 0.025% Vehicle

Updated 7 times since 2017 Last updated: Mar 2, 2012 Started: Jan 31, 2011 Primary completion: Mar 31, 2011 Completion: Mar 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Allergic Conjunctivitis and is currently completed. Eye Therapies, LLC leads this study, which shows 7 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eye Therapies, LLC
ORA, Inc.

Data source: Eye Therapies, LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Andover, United States